Spots Global Cancer Trial Database for liposomal doxorubicin
Every month we try and update this database with for liposomal doxorubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | NCT00635193 | Ovarian Cancer,... | M200 (Volocixim... Liposomal Doxor... M200 (Volocixim... M200 (Volocixim... | 18 Years - | AbbVie | |
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | NCT01215344 | Multiple Myelom... | VELCADE Lenalidomide Dexamethasone DVT prophylaxis Bisphosphonates Liposomal doxor... Dexamethasone | 18 Years - 70 Years | Vanderbilt-Ingram Cancer Center | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD) | NCT06235047 | Classic Hodgkin... | 60 Years - | Federico II University | ||
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer | NCT00465673 | Breast Cancer | Liposomal Doxor... | 21 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | NCT00401635 | Endometrial Can... | liposomal doxor... carboplatin | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer | NCT00350948 | Ovarian Neoplas... | Telcyta Liposomal Doxor... | 18 Years - | Telik | |
| R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | NCT02428751 | Lymphoma, Large... | Pegylated lipos... Doxorubicin Rituximab Cyclophophamide Vincristine Prednisone | 60 Years - 80 Years | Sun Yat-sen University | |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | NCT03618550 | Hodgkin Lymphom... Relapsed or Ref... | pembrolizumab gemcitabine vinorelbine liposomal doxor... Stem cell mobil... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | NCT00258960 | Breast Cancer | Liposomal Doxor... Cyclophosphamid... Trastuzumab | 18 Years - 75 Years | Spanish Breast Cancer Research Group | |
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | NCT05864534 | Newly Diagnosed... Glioblastoma, I... Gliosarcoma Glioblastoma Mu... | Balstilimab Botensilimab Liposomal Doxor... Sonocloud-9 (SC... | 18 Years - | Northwestern University | |
| A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | NCT01110603 | Cancer: Solid T... | MK-4827 carboplatin paclitaxel liposomal doxor... | 18 Years - | Tesaro, Inc. | |
| CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | NCT00434031 | Breast Cancer | docetaxel cyclophosphamid... trastuzumab liposomal doxor... | 18 Years - 65 Years | National Cancer Institute, Naples | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | NCT00092222 | Lymphoprolifera... HHV-8 Malignancy HIV | Etoposide Interferon-alph... Rituximab Zidovudine Liposomal Doxor... Bortezomib Valganciclovir Doxorubicin Vincristine Cyclophosphamid... Filgrastim (G-C... Prednisone Sirolimus Observation Onl... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | NCT06312176 | Breast Neoplasm... | Sacituzumab tir... Pembrolizumab Paclitaxel Nab-paclitaxel Capecitabine Liposomal doxor... | 18 Years - | Merck Sharp & Dohme LLC | |
| Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | NCT00886028 | Malignant Pleur... | Liposomal doxor... Cisplatin | 18 Years - 80 Years | National Institute of Cancerología | |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | NCT01215344 | Multiple Myelom... | VELCADE Lenalidomide Dexamethasone DVT prophylaxis Bisphosphonates Liposomal doxor... Dexamethasone | 18 Years - 70 Years | Vanderbilt-Ingram Cancer Center | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | NCT02659930 | Kaposi Sarcoma | liposomal doxor... pomalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer | NCT02488564 | HER-2 Positive ... | Liposomal doxor... Docetaxel Trastuzumab Metformin | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Trial of Myocet in Metastatic Breast Cancer | NCT00294996 | Breast Cancer | Myocet | 18 Years - | Sopherion Therapeutics | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | NCT00426127 | Pancreatic Canc... | Docetaxel Liposomal Doxor... Enoxaparin | 18 Years - | University of Iowa | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | NCT01669239 | Breast Cancer | Liposomal Doxor... | 18 Years - 74 Years | SOLTI Breast Cancer Research Group | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | NCT00507962 | Advanced Cancer | Cisplatin Liposomal Doxor... | - | M.D. Anderson Cancer Center | |
| AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | NCT00976911 | Ovarian Cancer | Bevacizumab liposomal doxor... paclitaxel topotecan | 18 Years - | Hoffmann-La Roche | |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | NCT00819221 | Solid Tumors | AZD2281 liposomal doxor... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging | NCT00531973 | Breast Cancer | liposomal doxor... epirubicin | 18 Years - 65 Years | Catholic University, Italy | |
| Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | NCT00758732 | Ovarian Cancer | Docetaxel Carboplatin Docetaxel Liposomal doxor... | 18 Years - | Hellenic Oncology Research Group | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | NCT03971409 | Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Invasive Breast... Recurrent Breas... Triple-Negative... Unresectable Br... | Anti-OX40 Antib... Avelumab Binimetinib Utomilumab Liposomal Doxor... Sacituzumab Gov... | 18 Years - | University of California, San Francisco | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | NCT00401635 | Endometrial Can... | liposomal doxor... carboplatin | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | NCT00575406 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin liposomal Doxor... Vincristin Prednisolone | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | NCT00507962 | Advanced Cancer | Cisplatin Liposomal Doxor... | - | M.D. Anderson Cancer Center | |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | NCT01490047 | Solid Tumors Lymphomas | Recombinant hum... Liposomal doxor... Caelyx Recombinant hum... | 18 Years - | Ludwig Institute for Cancer Research | |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | NCT00575406 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin liposomal Doxor... Vincristin Prednisolone | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| DOXIL for Consolidation Therapy in Ovarian Cancer. | NCT00248248 | Ovarian Neoplas... | liposomal doxor... | 18 Years - | Southeastern Gynecologic Oncology | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | NCT01669239 | Breast Cancer | Liposomal Doxor... | 18 Years - 74 Years | SOLTI Breast Cancer Research Group | |
| MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | NCT00326456 | Ovarian Cancer | liposomal doxor... carboplatin paclitaxel | - 75 Years | National Cancer Institute, Naples | |
| A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin | NCT04069845 | Lymphoma | liposomal doxor... | 18 Years - 80 Years | Ruijin Hospital | |
| Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer | NCT00193037 | Breast Cancer | Liposomal Doxor... Docetaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | NCT01110603 | Cancer: Solid T... | MK-4827 carboplatin paclitaxel liposomal doxor... | 18 Years - | Tesaro, Inc. | |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | NCT02186834 | Multiple Myelom... | Selinexor Liposomal doxor... Dexamethasone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial of Myocet in Metastatic Breast Cancer | NCT00294996 | Breast Cancer | Myocet | 18 Years - | Sopherion Therapeutics | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | NCT00886028 | Malignant Pleur... | Liposomal doxor... Cisplatin | 18 Years - 80 Years | National Institute of Cancerología | |
| Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen | NCT05731258 | Breast Cancer Liposomal Doxor... Efficacy Safety Postoperative A... | Liposomal doxor... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00903630 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Lenalidomide liposomal doxor... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | NCT02331251 | Advanced Cancer Breast Cancer Sarcoma Pancreatic Canc... Small Cell Lung... Ovarian | Pembrolizumab Gemcitabine Docetaxel Nab-paclitaxel Vinorelbine Irinotecan Liposomal Doxor... | 18 Years - | Western Regional Medical Center | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | NCT03539328 | Ovarian Cancer | Pembrolizumab Gemcitabine Paclitaxel Liposomal Doxor... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | NCT00191607 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | NCT00092222 | Lymphoprolifera... HHV-8 Malignancy HIV | Etoposide Interferon-alph... Rituximab Zidovudine Liposomal Doxor... Bortezomib Valganciclovir Doxorubicin Vincristine Cyclophosphamid... Filgrastim (G-C... Prednisone Sirolimus Observation Onl... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | NCT05949021 | Triple Negative... | Combination of ... | - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
